Gilead Sciences, Inc. (NASDAQ:GILD’s Sovaldi has stayed in repeated controversies for its pricing since the time it was launched in market. The discussion over Sovaldi’s pricing sees no end. However, amidst all these things the one fact that stands undisputable is the treatment works well on the patients. If the treatment is working well, the expensive hepatitis C cure will be sought by the patients and the medical industry in any case. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 0.13%. On last trading day company shares ended up $82.16. Analysts mean target price for the company is $100.26. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 9.48%.
Cell Therapeutics Inc (NASDAQ:CTIC) reported revenue of $1.4 million, compared to revenue of $1.1 million for the same period in 2013. The net loss for the first quarter of 2014 was $29.0 million (which included a $7.8 million non-cash share-based compensation expense), or ($0.20) per share, compared to $19.4 million, or ($0.18) per share, for the same period in 2013. Cell Therapeutics Inc (NASDAQ:CTIC) shares advanced 9.79% in last trading session and ended the day on $3.14. CTIC Gross Margin is 99.40% and its return on assets is -90.10%. Cell Therapeutics Inc (NASDAQ:CTIC) quarterly performance is -13.02%.
Dyax Corp. (NASDAQ:DYAX) shares are jumping, after rival Biocryst reported positive findings in the clinical trial for its hereditary angioedema (HAE) drug BCX416. Dyax Corp. (NASDAQ:DYAX) shares moved up 27.42% in last trading session and was closed at $8.41, while trading in range of $6.69 – $8.48. Dyax Corp. (NASDAQ:DYAX) year to date (YTD) performance is 11.54%.
On 26 MAY BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) awarded a special bonus (the “Special Award”) to all BioCryst employees. The Special Award has been paid as consideration for the significant progress in advancing the Company’s programs, and in particular, the recent successful execution of the Company’s BCX4161 OPuS-1 clinical trial. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ended the last trading day at $9.99. Company weekly volatility is calculated as 7.49% and price to cash ratio as 19.11. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) showed a positive weekly performance of 14.83%.
MannKind Corporation (NASDAQ:MNKD) announced that it will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York. Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD) weekly performance is 8.25%. On last trading day company shares ended up $8.00. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 26.69%.